UNASSIGNED: 6523 Background: Complete remission rates similar to those of younger pts are obtained in elderly AML pts (OSHO AML 1997). However, @entity3012 and @entity1778 remain dismal because of extremely high relapse rates. In the AML 2004 study, reduced intensity conditioning @entity12497 was introduced to reduce relapse in @entity1 with a compatible related/unrelated donor. In this analysis we compared outcome of @entity1 with a donor to @entity1 without a donor. METHODS: Of the 663 pts, 597 were entered into the study specific arm and 66 in the common arm of the German Intergroup Study. Of those 447 and 52 pts were evaluable, respectively. The majority of pts were male (56.9%), the median age 68 years and the median Karnofsky score 80%. Karyotype was normal in 46.9% and unfavorable in 21.2%, while 55.9% had de novo AML. Induction therapy consisted of @entity2592 100 mg/m(2) c. i. over 7 days / @entity5699 60 mg/m(2) i.v. on days 3 - 5 in the standard arm and of AraC 2g/m(2) on days 1, 3, 5 and 7 / @entity2664 10 mg/m(2) i.v. day 1 - 3 in the study arm. @entity12497 were performed following reduced intensity conditioning. RESULTS: CR was observed in 62% of pts after induction in the study arm and in 62% in the standard arm. A total of 76 pts had a stem cell donor and 129 no donor. There was no significant difference between the populations except for median age 68 in the chemotherapy vs. 65 a in the @entity12497 arm (p<0.001). @entity3012 at 3 a was 35    6% in the chemotherapy compared to 49    6% in the @entity12497 arm. Accordingly, @entity1778 at 3 a was 27    5% for chemotherapy as compared to 39    7% in the @entity12497 arm (p=0.04) and due to reduced relapse incidence (73  5% vs. 45  7%, respectively; p 0.001). Only @entity12497 and favorable risk cytogenetics were independent factors for increased @entity1778 . Both variables were independent risk factors for lower relapse rate, as was de novo AML. In contrast, high WBC at diagnosis and @entity12497 were significantly associated in a multivariate analysis with increased treatment related mortality. CONCLUSIONS: @entity12497 in comparison to chemotherapy is associated with increased @entity1778 and lower relapse independently of cytogenetic risk. The biggest differences in @entity1778 and relapse between @entity12497 and chemotherapy were noted among pts with high risk cytogenetic disease.

Relapse incidence and @entity1778 ( @entity1778 ) in XXXX (pts) older than age 60 with AM undergoing stem cell transplantation: A report of the East German Study Group Hematology and Oncology (OSHO).

@entity1 :: ('9606', 'Species') :: ['patients'] @entity12497 :: ('MESH:C535780', 'Disease') :: ['SCT'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['OS'] @entity5699 :: ('MESH:D003630', 'Chemical') :: ['Daunorubicin'] @entity2664 :: ('MESH:D008942', 'Chemical') :: ['mitoxantrone'] @entity2592 :: ('MESH:D003561', 'Chemical') :: ['AraC'] @entity1778 :: ('MESH:D007938', 'Disease') :: ['LFS']
@entity1 :: (9606,Species) :: ['patients']
